Nature Search

Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer

Huang et al. analyzed serial samples from participants with metastatic non-small cell lung cancer treated with radiotherapy followed by immunotherapy and report improved clinical outcomes and enhanced antitumor responses in immunologically cold tumors.

Justin Huang
Willemijn S. M. E. Theelen
Valsamo Anagnostou
ResearchOpen Access22 Jul 2025
Nature Cancer

Volume: 6, P: 1676-1692
Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial

Landon, Boland et al. investigate the clinical and molecular impact of a combination of epigenetic modulation and immune checkpoint inhibition in platinum-resistant ovarian cancer. Serial transcriptomic analyses reveal reshaping of the tumor microenvironment toward a more inflammatory state that may enhance immunotherapy response.

Blair V. Landon
Julia L. Boland
John A. Glaspy
ResearchOpen Access06 Feb 2026
Communications Medicine

Volume: 6, P: 1-12
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses

In a phase Ib trial, neoadjuvant nivolumab or nivolumab/relatlimab prior to chemoradiotherapy were well tolerated and liquid biopsy analyses show that undetectable ctDNA was associated with longer survival.

Ronan J. Kelly
Blair V. Landon
Vincent K. Lam
ResearchOpen Access19 Mar 2024
Nature Medicine

Volume: 30, P: 1023-1034
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results

In the first stage of the BR.36 adaptive trial in patients with non-small cell lung cancer receiving anti-PD1 immunnotherapy, the primary endpoint of concordance between circulating tumor DNA (ctDNA) molecular response and RECIST response was met. The results will inform the second, ctDNA-directed stage.

Valsamo Anagnostou
Cheryl Ho
Janet Dancey
ResearchOpen Access09 Oct 2023
Nature Medicine

Volume: 29, P: 2559-2569
Persistent mutation burden drives sustained anti-tumor immune responses

Genomic analyses in large cohorts of patients with cancer identify a new measure of tumor mutational burden, based on genomic regions that are unlikely to undergo loss, that is associated with therapeutic response to immunotherapy.

Noushin Niknafs
Archana Balan
Valsamo Anagnostou
ResearchOpen Access26 Jan 2023
Nature Medicine

Volume: 29, P: 440-449
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

In a phase 2 trial, the combination of chemotherapy with durvalumab, an anti-PD-L1 antibody, exhibited promising clinical activity in patients with previously untreated, unresectable mesothelioma, with additional analyses providing insights into genomic and immunologic features potentially associated with response.

Patrick M. Forde
Valsamo Anagnostou
Suresh S. Ramalingam
ResearchOpen Access08 Nov 2021
Nature Medicine

Volume: 27, P: 1910-1920

Search

Filter By:

Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer

Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results

Persistent mutation burden drives sustained anti-tumor immune responses

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

Search

Quick links